Transaction DateRecipientSharesTypePriceValue
1st October 2020Susan Elizabeth Arnold5,423Exercise of derivative$1.15$6,236.45
21st August 2020Jonathan P Mow10,000Exercise of derivative$1.24$12,400.00
14th August 2020John P Sharp5,000Exercise of derivative$1.69$8,450.00
27th February 2020Susan Elizabeth Arnold5,423Exercise of derivative$1.15$6,236.45
22nd November 2019Clay Thorp1,518,026Grant/award etc.$1.05$1,599,999.40
6th September 2019Jonathan P Mow19,000Exercise of derivative$1.24$23,560.00
21st August 2019John P Sharp10,000Exercise of derivative$1.69$16,900.00
21st August 2019John P Sharp5,000Exercise of derivative$1.44$7,200.00
1st July 2019Clay Thorp180Open or private sale$14.00$2,520.00
1st July 2019Clay Thorp2,014Open or private sale$14.00$28,196.00
Phase Bio Pharmaceuticals
Phase Bio Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in 2002.

Ticker: PHAS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1169245
Employees: 40
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $53 M (0%)
Assets, Current: $64 M (-19%)
Property, Plant and Equipment, Net: $5 M (0%)
Other Assets, Noncurrent: $57 Th (78%)
Assets: $71 M (-14%)
Long-term Debt, Current Maturities: $5 M (110%)
Accounts Payable, Current: $7 M (138%)
Liabilities, Current: $18 M (109%)
Long-term Debt, Excluding Current Maturities: $10 M (-20%)
Other Liabilities, Noncurrent: $388 Th (91%)
Liabilities: $44 M (97%)
Common Stock, Value, Issued: $29 Th (0%)
Common Stock, Shares, Issued: $29 M (0%)
Retained Earnings (Accumulated Deficit): $205 M (0%)
Treasury Stock, Value: $240 (0%)
Treasury Stock, Shares: $300 Th (0%)
Stockholders' Equity (Parent): $26 M (0%)
Liabilities and Equity: $71 M (-14%)
Revenue: $0 (-100%)
Research and Development: $21 M (-35%)
General and Administrative Expenses: $3 M (-49%)
Operating Income/Loss: $24 M (-37%)